415 reports of this reaction
1.9% of all CARBOXYMETHYLCELLULOSE SODIUM reports
#13 most reported adverse reaction
DRY EYE is the #13 most commonly reported adverse reaction for CARBOXYMETHYLCELLULOSE SODIUM, manufactured by Allergan, Inc.. There are 415 FDA adverse event reports linking CARBOXYMETHYLCELLULOSE SODIUM to DRY EYE. This represents approximately 1.9% of all 22,264 adverse event reports for this drug.
Patients taking CARBOXYMETHYLCELLULOSE SODIUM who experience dry eye should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRY EYE is a less commonly reported adverse event for CARBOXYMETHYLCELLULOSE SODIUM, but still significant enough to appear in the safety profile.
In addition to dry eye, the following adverse reactions have been reported for CARBOXYMETHYLCELLULOSE SODIUM:
The following drugs have also been linked to dry eye in FDA adverse event reports:
DRY EYE has been reported as an adverse event in 415 FDA reports for CARBOXYMETHYLCELLULOSE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRY EYE accounts for approximately 1.9% of all adverse event reports for CARBOXYMETHYLCELLULOSE SODIUM, making it a notable side effect.
If you experience dry eye while taking CARBOXYMETHYLCELLULOSE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.